CD27 and neoplasm: Anti-CD70 mAB treatment blocks CD70-CD27 signaling, interferes with lipid metabolism, suppresses Tregs secretory profiles and expression of suppressor molecules, and significantly improves anti-tumor immunity in combination with anti-PD-1 mAB treatment [112].